Interleukin-10 as a CNS therapeutic: the obstacle of the blood-brain/blood-spinal cord barrier.
Interleukin (IL)-10 exerts beneficial effects on the central nervous system (CNS) after peripheral administration, but its penetration across the blood-brain barrier (BBB) has not been quantified. We show that 125I-IL-10 is stable in circulating blood but does not cross the intact BBB after intravenous delivery. Thus, peripheral IL-10 probably can serve as a CNS therapeutic only when the BBB is disrupted.
Kastin
Abba J
AJ
VA Medical Center and Tulane University School of Medicine, 1601 Perdido Street, New Orleans, LA 70112-1262, USA. peptides@tulane.edu
Akerstrom
Victoria
V
Pan
Weihong
W
D000418:Albumins / Q000493:pharmacokinetics; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001927:Brain Diseases / Q000188:drug therapy; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D004058:Diffusion / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D016753:Interleukin-10 / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007457:Iodine Radioisotopes; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D008657:Metabolic Clearance Rate / Q000187:drug effects; D051379:Mice; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013667:Technetium
D000418:Albumins; D007457:Iodine Radioisotopes; D008563:Membrane Lipids; D016753:Interleukin-10; D013667:Technetium